Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Headaches Clinical Trials

A listing of Headaches medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (229) clinical trials

Dr. Craig LaForce and Dr. Karen Dunn are recruiting individuals 18-75 years old who have a diagnosis of Migraine headaches to participate in a research study involving an investigational medication.

Phase N/A

Does your child get migraines? The purpose of this research study is to measure how effective and how safe investigational zolmitriptan nasal spray is for acute migraine headaches in children ages 6 to 11 years old. This study requires up to 7 visits over 11 months.

Phase

People with Cluster Headaches are asked to participate in a registry being conducted by Montefiore Medical Center.

Phase N/A

Acute Migraines – Moderate to Severe

Phase N/A

Are your migraines not under control? Wake Research Associates is enrolling volunteers with migraines in a research study testing an investigational medication.   Other Details:Qualified participants may receive:-Study-related medication at no cost-Study-related medical exams at no cost-Compensation for time and travelInsurance is not needed to participate in this study

Phase N/A

  In this research study, doctors want to test the safety and effectiveness of the study drug for the acute treatment of Migraine.    Length of study: up to 54 weeks   Number of office visits: up to 18 visits   At no cost, qualified participants will receive:   Study-related ...

Phase N/A

Protocol:  IPX229-B16-01 This is a study to evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in subjects ages 6 to 11 years.

Phase

Protocol #: 20150308 Migraine prevention in Subjects with Chronic Migraine (CM) or Episodic Migraine (EM) comparing the treatment medication AMG 301 to placebo.

Phase

Rimegepant is being developed for the treatment of migraine, with a specific focus on acute treatment. Effectiveness against migraine was demonstrated in a Phase 2b double-blind, randomized, placebocontrolled, dose-ranging study where rimegepant at 75 mg showed efficacy on all four traditional endpoints: pain, nausea, photophobia and phonophobia.

Phase

To assess the single dose PK of galcanezumab administered via subcutaneous injection in a population of pediatric patients aged 6 to 17 years with migraine

Phase